The efficacy and safety of microneedling with topical tranexamic acid for melasma treatment: A systematic review and meta‐analysis

Author:

Feng Xiaowei1,Su Hong1,Xie Jinwei2

Affiliation:

1. Department of Dermatovenerology Chengdu First People's Hospital Chengdu China

2. Department of Orthopedics surgery West China Hospital of Sichuan University Chengdu China

Abstract

AbstractObjectiveMicroneedling with topical tranexamic acid (TXA) is a novel treatment option for melasma; however, the efficacy and safety of this combined administration therapy is in controversial. This study is conducted to address this issue of this technique in melasma.MethodsAn extensive literature review was performed to identify relevant trials, including randomized split‐face studies, randomized controlled trials and prospective non‐randomized split‐face studies, comparing microneedling plus topical TXA to routine treatments or placebo. The primary outcomes were changes of the Melasma Area Severity Index (MASI)/modified MASI (mMASI)/hemi MASI between before and after treatment, as well as the changes between a particular treatment and microneedling plus TXA. The mean differences (MDs) and 95% confidence intervals (CIs) were calculated for the reduction of melasma severity scores from baseline to each time point. In contrast, the standard mean differences (SMDs) and 95% CIs were calculated for the differences in reduction in melasma severity scores between the experimental and control groups at each time point.ResultsA total of 16 trials were included in the systematic review and data synthesis. The pooled analysis demonstrated that MASI, mMASI, and hemiMASI scores decreased significantly at 4 weeks (MD = 1.85; 95% CI = 1.15–2.54), 8 weeks (MD = 3.28; 95% CI = 2.31–4.24), 12 weeks (MD = 4.73; 95% CI = 2.79–6.50), 16 weeks (MD = 3.18; 95% CI = 1.50–4.85), and 20 weeks (MD = 3.20; 95% CI = 1.95–4.46) after treatment when compared with baseline. The reduction in melasma severity scores of microneedling with TXA group at 4 weeks was more significant than the routine treatment group (SMD = 0.97; 95% CI = 0.09–1.86), while insignificant at 8 weeks (SMD = 1.21; 95% CI = −0.17 to 2.59), 12 weeks (SMD = 0.63; 95% CI = −0.03 to 1.29), 16 weeks (SMD = 0.61; 95% CI = −2.85 to 4.07), or 20 weeks (SMD = 1.04; 95% CI = −1.28 to 3.36).ConclusionDespite the high heterogeneity across these studies, the current findings indicated that microneedling with topical TXA is an alternative treatment option for melasma treatment; and more well‐designed studies are needed to confirm it.

Publisher

Wiley

Subject

Dermatology

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Different administration routes of tranexamic acid in the treatment of melasma;Chinese Journal of Plastic and Reconstructive Surgery;2024-09

2. Melasma: A Step-by-Step Approach Towards a Multimodal Combination Therapy;Clinical, Cosmetic and Investigational Dermatology;2024-05

3. Mesotherapy for Melasma – An Updated Review;Journal of Pharmacy and Bioallied Sciences;2024-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3